Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 4/20 | 0.61 |
| ▸ | TSHR | P16473 | 2/20 | 0.61 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 1/20 | 0.61 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 11/20 | 0.59 |
| ▸ | PPARG | P37231 | 3/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.41 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31357584 | 1.00 | PPARA (0.61) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL21991238 | 0.85 | PPARA (0.59) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL18524209 | 0.83 | PPARA (0.57) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL23124792 | 0.83 | FBP1 (0.41) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL198547 | 0.82 | PPARA (0.58) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL16585114 | 0.81 | PPARA (0.56) | PPARATSHRCYP1A2CYP3A4PPARG | |
| SCHEMBL1712071 | 0.81 | PPARA (0.57) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL31117791 | 0.81 | PPARA (0.65) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL16585155 | 0.80 | PPARA (0.39) | PPARATSHRABCB11CYP1A2CYP3A4 | |
| SCHEMBL1549344 | 0.80 | PPARA (0.56) | PPARATSHRABCB11CYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | LG CHEM, LTD. (KR) | 2026-05-19 | — | — | US | disclosed |
| EP-4071147-B1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEMICAL LTD (KR) | 2025-03-26 | — | — | EP | disclosed |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | LG CHEM, LTD. (KR) | 2023-03-16 | — | — | US | disclosed |
| EP-4071147-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | Lg Chem, Ltd. (KR) | 2022-10-12 | — | — | EP | disclosed |
| CN-114846013-A | Novel aminoaryl derivatives useful as diacylglycerol acyltransferase 2 inhibitors and uses thereof | 株式会社LG化学 | 2022-08-02 | — | — | CN | disclosed |
| WO-2021133035-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | 주식회사 엘지화학 | 2021-07-01 | — | — | WO | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-9994558-B2 | Multicyclic compounds and methods of using same | Karyopharm Therapeutics Inc. (US) | 2018-06-12 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | Karyopharm Therapeutics Inc. (US) | 2017-04-06 | — | — | US | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
| WO-2015042414-A1 | MULTICYCLIC COMPOUNDS AND METHODS OF USING SAME | Karyopharm Therapeutics Inc. (US) | 2015-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170096417-A1 | Multicyclic Compounds And Methods Of Using Same | PAK4, PAK5, PAK1 | PPARA 2518/4885TSHR 4639/4885ABCB11 699/4885 |
| US-20230078941-A1 | NOVEL AMINO ARYL DERIVATIVE USEFUL AS DIACYLGLYCEROL ACYLTRANSFERASE 2 INHIBITOR AND USE THEREOF | DGAT2, DGAT1, PLAAT2 | PPARA 295/4885TSHR 2981/4885ABCB11 1233/4885 |
| US-12630528-B2 | Amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof | DGAT2, DGAT1, SOAT2 | PPARA 421/4885TSHR 2229/4885ABCB11 697/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.